Objective The Mutanome Engineered RNA Immuno-Therapy (MERIT) project aims to clinically translate and industrially validate a pioneering RNA-based immunotherapy approach to target the individual tumour antigen signature. MERIT focuses on previous inventions, fits into the overall business and innovation needs of the partners, and addresses triple-negative breast cancer patients with high medical need. The MERIT concept, including patents and potential products, was developed using EU FP6 funding. The innovative therapeutics will pave the way for generation of scientific knowledge and technologies and will stimulate the development of new products, tools, patents, and innovative marketable applications.The concept behind MERIT is to implement a highly innovative Next-Generation-Immunotherapy drug platform enabling Next–Generation-Sequencing-guided stratified medicine and clinical-grade individualized RNA vaccines. Every patient’s tumour expresses many shared tumour-specific antigens and bears a highly individual molecular “signature” comprising 10’s to 100’s of non-synonymous mutations, many of which are immunogenic. We will use clinical-grade RNA to produce a) a warehouse of therapeutic vaccines targeting shared antigens and b) custom therapeutic vaccines targeting patient-specific mutations. Upon success, partner BioNTech will move the therapeutics to advanced clinical trials and commercial applications for the benefit of triple negative breast cancer patients and other solid tumours. Fields of science medical and health sciencesclinical medicineoncologybreast cancermedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesnatural sciencesbiological sciencesgeneticsmutationnatural sciencesbiological sciencesgeneticsRNAmedical and health sciencesbasic medicineimmunologyimmunotherapy Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Topic(s) HEALTH.2013.0-1 - Boosting the translation of health research projects' results into innovative applications for health Call for proposal FP7-HEALTH-2013-INNOVATION-2 See other projects for this call Funding Scheme CP-FP - Small or medium-scale focused research project Coordinator BIONTECH AG EU contribution € 4 456 750,00 Address HOLDERLINSTRASSE 8 55131 Mainz Germany See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Ugur Sahin (Prof.) Links Contact the organisation Opens in new window Total cost No data Participants (4) Sort alphabetically Sort by EU Contribution Expand all Collapse all INSTITUT GUSTAVE ROUSSY France EU contribution € 453 750,00 Address Rue Camille Desmoulins 39 94805 Villejuif See on map Region Ile-de-France Ile-de-France Val-de-Marne Activity type Research Organisations Administrative Contact Arnauld Forest (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data VRIJE UNIVERSITEIT BRUSSEL Belgium EU contribution € 401 250,00 Address PLEINLAAN 2 1050 Bruxelles / Brussel See on map Region Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad Activity type Higher or Secondary Education Establishments Administrative Contact Nik Claesen (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data University of Zurich Switzerland EU contribution € 315 000,00 Address RAMISTRASSE 71 8006 ZURICH See on map Activity type Higher or Secondary Education Establishments Administrative Contact Steve Pascolo (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data UPPSALA UNIVERSITET Sweden EU contribution € 337 500,00 Address VON KRAEMERS ALLE 4 751 05 Uppsala See on map Region Östra Sverige Östra Mellansverige Uppsala län Activity type Higher or Secondary Education Establishments Administrative Contact Pirkko Boox (Mrs.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data